| Pharmaceutical Information |
| Drug Name |
Fedratinib |
| Drug ID |
BADD_D02554 |
| Description |
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative.[A183188]
Fedratinib was granted FDA approval on August 16, 2019.[L8090] |
| Indications and Usage |
Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high risk.[L8090] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EJ02 |
| DrugBank ID |
DB12500
|
| KEGG ID |
D10630
|
| MeSH ID |
C528327
|
| PubChem ID |
16722836
|
| TTD Drug ID |
D0G8BM
|
| NDC Product Code |
Not Available |
| UNII |
6L1XP550I6
|
| Synonyms |
Fedratinib | N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide | TG101348 | SAR302503 | fedratinib hydrochloride | Inrebic |
|
| Chemical Information |
| Molecular Formula |
C27H36N6O3S |
| CAS Registry Number |
936091-26-8 |
| SMILES |
CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
